BRAF and melanoma: We discovered that AR42, at approximately 40% of its plasma C max within 6h reduced the expression of the immuno-regulatory proteins PD-L1 and to a lesser extent PD-L2 on PDX models of mutant B-RAF melanoma in vitro, which could in theory facilitate an immunological anti-tumor response (Figure 3A).